Downregulation of endothelin-1 by somatostatin improves liver function of recipients undergoing adult-to-adult living donor liver transplantation

What Was Tested

The paper reports a study of Somatostatin and Endothelin-1, published as a randomized controlled trial.

The aim of this study was to investigate the possible effect of somatostatin on the liver function of recipients undergoing living donor liver transplantation.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Somatostatin and who got the comparison, which limits bias.

Forty recipients were randomized into group A (n = 20) and group B (n = 20).

Recipients in group A received no somatostatin whereas somatostatin was administrated for recipients in group B perioperatively.

Liver function, the plasma concentration of endothelin-1 and nitric oxide, the intragraft expressions of endothelin-1 and inducible nitric oxide syntheses at 2 hours after declamping of the portal vein were compared between the two groups.

What Was Measured

Topics PubMed links to this paper include Down-Regulation, Endothelin-1, Hormones, Immunohistochemistry, Liver, Liver Transplantation and Living Donors.

What This Means in Plain Language

The paper is a randomized study of Somatostatin and Endothelin-1.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2010 (Chinese medical journal), a journal based in China.

More context: the Somatostatin compound page and the Endothelin-1 compound page, all human trials.